Next Generation Sequencing Market to Reflect Impressive Growth Rate by 2023

Next generation sequencing (NGS) also known as high-throughput sequencing enables scientists to sequence and assemble billions of short DNA reads. The advent of next generation sequencing technologies has brought significant changes in the sequencing process by providing high throughput, speed, flexibility and reduced sequencing cost over thousand folds. NGS has ability to generate hundreds of gigabases of nucleotide sequence data in a single sequencing run. The technology is emerging at a rapid rate due to its growing adoption in clinical applications as it allows scanning of whole genomes or targeted genomes in less span of time. In addition, reduction in cost of sequencing has also expanded the usage of next generation sequencing in variety of clinical applications. The technique has imparted its usage in various clinical applications such as cancer, inherited genetic disorders, HLA typing and identification of infectious diseases. For instance, NGS has been used for tracing hospital acquired infections and tuberculosis outbreaks.

The market for next generation sequencing can be segmented based on technology, application, end-users and geography. The application section can be categorized into drug discovery, personalized medicines, biomarker discovery, diagnostics and others (agriculture, animal, marine and other studies). The technology section of the market could be subdivided into sequencing by synthesis, ion semiconductor sequencing, pyrosequencing, sequencing by ligation and single molecule real time sequencing. The next generation sequencing market can also be analyzed based on the end user segment including hospitals and clinics, research institutions and pharmaceutical and biotechnology companies. It is witnessed that more than 65% of the next generation sequencing revenue is generated from academic institutions, biopharmaceutical companies and government research institutes. Geographically, the market is segmented into North America, Europe, Asia-Pacific, Latin America (LATAM), and Middle East and Africa (MENA). Of all the geographies, North America accounted for the largest market share in 2014 followed by Europe. However, during the forecast period Asia-Pacific region is anticipated to record highest growth owing to market saturation in developed regions. Furthermore, technological innovation, increasing drug discovery initiatives by healthcare companies, increasing adoption of innovative models and huge capital investment by pharmaceutical and biotechnology companies are some of the key factors expected to drive the growth of next generation sequencing market in Asia.

Currently, the next generation sequencing market is consolidated with very few market players due to involvement of extremely complicated technologies and the low target audience for the systems. The expensive next-generation sequencing systems may exceed a cost of millions of dollars for installation, maintenance, reagents and output analysis. Most respondents have suggested sequencing as a service business rather than an investment for in-house research. Introduction of bench-top sequencers enabling ease of use to researchers is also expected to push the market growth further. Outsourcing sequencing is expected to remain a major contributor to the revenue generation in the coming years. Response gathered from research facilities suggest that purchase of these sequencing platforms may demonstrate actual growth post reduction in the sequencing costs below USD 1000 as suggested by several manufacturers. True potential of this technology lies in the personalized medicine and sequencing genomes of individuals. Furthermore, increasing initiatives by government bodies for genomics research would also boost the adoption of high-throughput sequencing platform.

Some of the major players operating in the global NGS market are Agilent Technologies, Life Sciences Corporation (Roche Holding Ag), Genomatix Software Gmbh, Illumina, Inc., Gatc Biotech Ag, Dnastar, Inc., Life Technologies Corporation, Oxford Nanopore Technologies, Ltd., Perkin Elmer, Inc., Qiagen N.V., Partek Incorporated, Macrogen, Inc., Knome, Inc., and Genomatix Software Gmbh.

Shreyas is a Digital Marketer by professional and he has a great experience in blogging, content writing and SEO

Tuberculosis Drugs Market to Reflect Impressive Growth Rate by 2025

Tuberculosis (TB) is an infectious disease, which is caused by Mycobacterium tuberculosis. These bacteria generally infect human lungs. However, it can infect other body parts/organs as well. Three major types of tuberculosis are found: latent, active, and drug-resistant tuberculosis. Symptoms are not identifiable in case of latent tuberculosis, due to presence of an inactive form of bacteria. In active tuberculosis, symptoms are clearly visible and they can spread from one person to another. Coughing for more than two weeks, chest pain, coughing up blood, chills, fatigue, unintentional weight loss, fever, and loss of appetite are some of the common symptoms of active tuberculosis. HIV/AIDS, severe kidney disease, cancer, diabetes, and malnutrition are some of the key risk factors generally found to be associated with tuberculosis.

Tuberculosis can be diagnosed with the help of tests including blood tests, imaging tests (such as chest X-ray or CT scan), and sputum tests. Tuberculosis can be treated with the first-line or second-line therapy. As per a report by World Health Organization (WHO), tuberculosis is one of the leading causes of deaths occurring worldwide. In 2015, approximately 9 million new cases of TB and 1.5 million deaths caused by TB occurred worldwide. Currently, WHO and certain government agencies are working toward reduction of tuberculosis burden globally, with the help of programs such as Stop TB. In December 2015, Multi-Drug Resistant Tuberculosis Program was also launched to check the tuberculosis prevalence across the globe.

Growing prevalence of multi-drug resistant tuberculosis is driving the tuberculosis drugs market. Drug shortages is a major restraint for the tuberculosis drugs market, especially in low- to medium-income countries of the world. Tuberculosis associated with diseases such as HIV/AIDS and conditions such as obesity is extremely difficult to manage. The tuberculosis drugs market can be segmented based on drug class, disease type, end-user, and region. In terms of drug class, the market can be categorized into first-line therapy, second-line therapy, and combination therapy. Isoniazid, Pyrazinamide, Rifampin, and Ethambutol majorly constitute the first-line therapy for TB; while Streptomycin, Capreomycin, Ethionamide, Levofloxacin, and Gatifloxacin are generally considered as a part of the second-line therapy. Second-line therapy is expected to be a rapidly growing segment of the tuberculosis drugs market.

Based on disease type, the tuberculosis drugs market can be segmented into latent tuberculosis, active tuberculosis, and drug-resistant tuberculosis. The drug-resistant tuberculosis segment is expected to expand rapidly during the forecast period. In terms of distribution channel, the market can be divided into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment held the leading share in the global tuberculosis drugs market in 2016. The segment is projected to expand at a significant CAGR during the forecast period. The others segment is expected to gain a significant market share during the forecast period, due to launch of national government programs.

In terms of geography, the global tuberculosis drugs market can be categorized into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific dominated the global tuberculosis drugs market in 2016. Key factors responsible for growth of the market in Asia Pacific are presence of large patient population and high incidence rate of TB, especially in some of the developing economies of the region such as India and China. On the other hand, North America and Europe have a relatively small-sized patient pool with lower incidence rate of the disease. However, high awareness, well-developed health care infrastructure, rapid adoption of advanced yet expensive TB tests, and high purchasing power are driving the market in these regions.

Key players operating in the global tuberculosis drugs market are Sanofi, Novartis AG, Bayer AG, Lupin Limited, Zydus Cadila, Merck & Co., Inc., Pfizer Inc., and AstraZeneca.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Shreyas is a Digital Marketer by professional and he has a great experience in blogging, content writing and SEO

Facial Injectables Market Estimated to Bring US$9.4 Bn by 2020


The strong desire to look younger is the most prominent factor propelling the global facial injectables market, says Transparency Market Research in its latest report. This 72-page research publication, titled “Facial Injectables Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020”, states that developing at a steady CAGR of 14.60% from 2014 to 2020, the global facial injectables market is projected to grow from a value of US$3.3 bn in 2013 to US$9.4 bn by 2020.

The market for facial injectables is also driven by the rising geriatric population, growing preference for minimally invasive procedures, and increasing longevity of the effects of facial injectable products. While product innovation and product development offer new avenues for growth, side effects of certain products have limited the adoption of facial injectables.

The facial injectables market is categorized on the basis of product into hyaluronic acid, polymers and particles (PPFs), botulinum toxin, and collagen. Hyaluronic acid is the largest segment of the facial injectables market and, registering a steady CAGR of 16.30% during the forecast period, this segment is anticipated to grow to a value of US$5.9 bn by 2020. Polymers and particles, on the other hand, are projected to form the fastest expanding product segment by the end of the forecast period owing to having less side effects than other facial injectable products and higher longevity of the effect.

The global facial injectables market is segmented on the basis of geography into Asia Pacific, North America, Europe, and Rest of the World. Accounting for a 40.9% share in 2013, North America dominates the overall market owing to the growing demand to look younger, presence of a large pool of geriatric population, higher rate of spending on aesthetic procedures, presence of highly advanced healthcare infrastructure, strict implementation of regulatory guidelines, and a well-structured regulatory framework. Asia Pacific has been identified as having the most opportunities in the facial injectables market and this region is projected to expand at the fastest pace during the forecast period. Countries such as India, South Korea, and China have greatly contributed towards the development of the Asia Pacific facial injectables market. This growth can be attributed to factors such as the rise in disposable income, presence of a large aging population base, increase in healthcare spending, rapidly developing healthcare infrastructure, a booming entertainment industry, and rising demand for aesthetic surgical procedures.

The research report highlights the key players who have contributed towards the growth of the global facial injectables market and analyzes them based on aspects such as company overview, product portfolio, business strategies, financial standing, and recent developments. The players profiled in the facial injectables market report are Merz Pharma GmbH & Co. KGaA, Bloomage BioTechnology Corporation Limited, Allergan, Inc., Galderma S.A., and Ipsen Group.

Shreyas is a Digital Marketer by professional and he has a great experience in blogging, content writing and SEO

Wound Treatment Market to Reflect Impressive Growth Rate by 2020


The global wound treatment market includes an array of products, each formulated to avoid an infection in a wound and heal it. Wounds are generally classified as acute or chronic. The global wound treatment market is categorized into the following segments: advanced, basic, bioactive, therapeutic, and traditional devices. The advanced wound treatment market can be further divided into hydrogels, foam wound care, moist wound care, alginates, hydrocolloid and hydrogels. Advanced wound treatment is budding as a regular way out for treating chronic wounds. Traditional wound treatment is being increasingly replaced with advanced wound treatment due to their better effectiveness and efficacy in treating wounds by allowing faster healing.

The global wound treatment market is driven by a variety of factors such as privileged incidences of hospital-acquired infections, rising aging population, increasing diabetic and obese population, government spending for advancement of wound treatment products, new materials used for product innovation and development in chemical and biological sciences resulting in growth of the market. The requirement for portable and easy to use devices is likely to drive the growth of wound treatment market. On the other hand, factors such as high costs of advanced wound treatment products and competiveness may inhibit the growth of these products in the global wound treatment market.

Geographically, the global wound treatment market is segmented into North America, Europe, Asia Pacific and Rest of the World. Asia Pacific is expected to grow rapidly, due to rising incidences of chronic diseases, increasing aging population, rising awareness for wound treatment products, and increasing population with pressure ulcers has enhanced the demand for wound treatment products. With respect to the advance wound treatment products the Asian market is predictable to observe moderate growth, due to forcing physicians and patients to choose for traditional treatment, and lack of reimbursement.

In addition, majority of the players are focusing on the Asian market. For example, in 2012, Smith & Nephew launched 23 new wound treatment products (such as single use Negative Pressure Wound Therapy (NPWT) system, pocket-sized PICO system) in the Asian markets. Also, in December 2012, ConvaTec India Private Limited started its operations in Bangalore, Karnataka, India, to convey new healthcare products, technologies, and healing treatment to the Indian market, thus establishing its trail in the Asian market. Such expansion is expected to drive the Asian wound care market in the upcoming years.

Some of the key global market participants present in the global wound treatment market includes Smith & Nephew plc, Baxter International, Inc., Ethicon, Inc., 3M Company, Covidien PLC, Derma Sciences, Inc., Coloplast A/S, Hollister, Inc., Convatec Healthcare B.S.A.R.L., Mölnlycke Health Care , Kinetic Concept, Inc and others.

Shreyas is a Digital Marketer by professional and he has a great experience in blogging, content writing and SEO

Nanomedicine Market to Reach a whopping US$177.60 Bn by 2019


According to a recent market research report released by Transparency Market Research, the global nanomedicine market is estimated to expand at a CAGR of 12.3% during the period between 2013 and 2019. The report, titled “Nanomedicine Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019”, projects the global nanomedicine market to be worth US$177.60 bn by 2019. The overall market was valued at US$78.54 bn in 2012.

The report points out that improvement in technology for nanomedicine has propelled the global nanomedicine market. Rising government support for research and development of nanomedicine, coupled with an increase in investment and healthcare collaborations, is expected to augment the growth of the market during the forecast horizon. High prevalence of chronic diseases and presence of high unmet medical needs will also push the market growth. However, the report notes that the lack of organized regulatory framework and high costs involved in the development of nanomedicine will hinder the growth of the global nanomedicine market during the forecast period. The market has a huge opportunity to grow in the emerging economies along with the identification of new medical applications.

On the basis of application, the report segments the global nanomedicine market into oncology, anti-inflammatory, neurology, cardiovascular, anti-infectives, and other applications. In 2012, the overall market was dominated by the oncology segment, which accounted for around 38.0% of the market. This can be attributed to the extensive usage of commercialized nanomedicine products in the field of oncology. However, during the next couple of years, the cardiovascular segment is expected to display the fastest growth owing to the growing geriatric population and increasing demand for nanomedicine-based devices and drugs for the treatment of cardiovascular diseases.

The report studies the global nanomedicine market according to its performance in four key regional segments: Asia Pacific, North America, Europe, and Rest of the World. In 2012, North America dominated the overall market and is expected to continue its dominance during the forecast horizon. Advanced healthcare infrastructure has attributed to the growth of the market in this region. However, during the period between 2013 and 2019, Asia Pacific is forecast to expand at a 14.6% CAGR and emerge as the fastest growing region in the market. Rising awareness about healthcare, coupled with growing prevalence of chronic diseases, has fuelled the nanomedicine market in the region. In countries such as India and China, increased research funding and numerous research collaborations in the field of nanomedicine will further push the market.

The report profiles some of the key players in the global nanomedicine market, such as CombiMatrix Corp, Abbott Laboratories, Celgene Corporation, Mallinckrodt plc, Johnson & Johnson, Merck & Co. Inc., GE Healthcare, Pfizer Inc., Nanosphere Inc., UCB SA, Sigma-Tau Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd. The report provides insightful information about the key players, including their financial overview, business strategy, product portfolio, and recent developments.

Shreyas is a Digital Marketer by professional and he has a great experience in blogging, content writing and SEO

Transcriptomics Technologies Market Slated to Value at US$4.6 Bn by the end of 2019

Transparency Market Research, a global market intelligence consultancy, has published a market study on the global transcriptomics technologies market for the 2013-2019 period. According to this report, the global transcriptomics technologies market will rise at a CAGR of 15.90% from 2013 to 2019 to reach a valuation of US$4.6 bn by the end of the forecast period. The market’s valuation in 2012 was US$1.65 bn. The report is titled “Transcriptomics Technologies Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019”.

The report says that the global transcriptomics technologies market will witness substantial growth in the coming years due to several reasons. Transcriptomics research involves studying the structure and function of RNA present in a cell.Presently, transcriptome analysis of several organisms is assisted using next-generation sequencing platforms in the preliminary phase followed by polymerase chain reactions, gene regulation technologies, and microarrays in the latter part. The coalition of these technologies is used for drug discovery, clinical diagnosis of diseases, medical research, and others. With the ever-increasing demand for targeted therapeutics and continual improvement of healthcare infrastructure, the commercial usage of transcriptomics technologies holds promise. Transcriptomics research allows the development of newer therapeutics and diagnostics and further advancement of the existing line of treatment for medical conditions.

The report says that in the transcriptomics technologies market, the key application segments undergo consistent development in order to offer added value to users. For instance, the utilization of transcriptomics technologies has benefitted the pharmaceutical and biotechnology fields; other fields are also deriving the advantages of this technology for mutual benefits of both the technology and the application field. Laboratories attempting to use biomarkers and newer gene sequencing methods is an example of this.

The need for the development of adequate equipment in healthcare organizations and laboratories, the growing awareness about transcriptomics technologies globally, and increased participation of government bodies in transcriptomics research are some other factors driving this global market.

However, growth of the transcriptomics technologies market is hampered due to certain factors cited in this report. These include the unavailability of advanced equipment needed for biological computation, unavailability of services essential to analyzing complex information, and an overall deficit of technicians that have expertise in the subject.

Shreyas is a Digital Marketer by professional and he has a great experience in blogging, content writing and SEO

Companion Diagnostics Market Slated to Value at US$5.6 Bn by the end of 2019

A new Transparency Market Research report states that the global companion diagnostics market stood at US$1.8 bn in 2013 and is predicted to reach US$5.6 bn by 2019. It is predicted to expand at a whopping CAGR of 18.0% between 2013 and 2019. The title of the report is “Companion Diagnostics Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019.”

As per the report, the increasing demand for personalized medicines is the key factor fuelling the growth of the market for companion diagnostics. In addition, the rising occurrence of cancer globally and the reducing costs of drug development are also augmenting the growth of the market.

Factors such as the rising focus on targeted therapies and the focus of pharmaceutical companies on the in-house advancement of companion diagnostics are also augmenting the growth of the market. Furthermore, the increasing new indication areas have emerged as a key opportunity in the market.

On the other hand, the increasing duration of the approval process and the prolonged development time of companion diagnostics may impede the growth of the market in forthcoming years. The unfavorable reimbursement scenario globally may also have a negative impact on the growth of the market in the coming years, as stated in this report.

Companion diagnostics are various procedures or tests utilized by healthcare professionals in making enhanced treatment decisions for patients as per the patients’ response to particular ongoing treatments. Companion diagnostics aid a health care professional to determine the effects of a specific therapeutic product on patients and any potential risks or side effects associated with its usage. The healthcare professional then adjusts his treatment to achieve enhanced effectiveness and safety.

On the basis of indication, the report segments the companion diagnostics market into lung cancer, breast cancer, gastric cancer, colorectal cancer, melanoma, and others including HIV and thalassemia. Amongst these, in 2012, the segment of breast cancer led the market on the basis of revenue. However, in forthcoming years, the segment of lung cancer will dominate the market, expanding at a CAGR of more than 20% between 2013 and 2019. This is owing to the discovery of myriad relevant companion diagnostics as well as the discovery of lung-cancer-specific biomarkers.

In terms of geography, the report segments the market into Europe, North America, Asia Pacific, and Rest of the World (RoW). Amongst these, in 2012, the market for companion diagnostics was dominated by the region of North America and this region held a share of over 35% in the market on the basis of revenue. This is because of the increasing consumer base due to the increasing count of cancer patients, rising affordability, increasing awareness about personalized healthcare, and the presence of sophisticated medical equipment in this region. On the other hand, the increased adoption of innovative medical procedures, the rising disposable incomes of consumers, and the rising healthcare infrastructure will also fuel the Latin America and Asia Pacific companion diagnostics markets.

According to the study, the chief players operating in the market are Roche Holdings AG, Qiagen N.V., Agilent Technologies, Inc., Agendia N.V., Abbott Laboratories, Genomic Health, Inc., GE Healthcare Ltd., and Life Technologies Corporation, among others.

Shreyas is a Digital Marketer by professional and he has a great experience in blogging, content writing and SEO

Automated Immunoassay Analyzers Market Slated to Value at US$3.78 Bn by the end of 2025

Only a handful of companies such as bioMerieux, Inc., Abbott Laboratories, and Roche Diagnostics enjoy stronghold in the global automated immunoassay analyzers market. The lead of the companies is attributable to their expansive regional footprint and product portfolio, finds Transparency Market Research (TMR) in a new study. Furthermore, with a strong financial muscle, these companies are looking toward brighter prospects in the near future. As these companies gear to emerge at the fore, the global automated immunoassay analyzers market may witness roll out of novel products. Besides this, customization of existing products is on cards well. Riding on these factors the global automated immunoassay analyzers market is forecast to showcase robust expansion in the coming years.

TMR has pegged the global automated immunoassay analyzers market at US$2.57 bn in 2016. Exhibiting a steady 4.5% CAGR between 2017 and 2025, the market is expected to reach US$3.78 bn by the end of 2025. During the course of this forecast period, Asia Pacific is likely to exhibit the highest CAGR of 4.9%. Among key end users, the market is expected to witness rising demand from diagnostic laboratories across the world.

Proliferation of Laboratory Consolidation to Enable Market Report Positive Trajectory

The accelerated pace of gains witnessed in the market is aided by diverse factors. For instance, the rising incidence of chronic ailments and disease epidemics such as hepatitis infection, Zica, and HIV are among the chief factors fuelling the demand for automated immunoassay analyzers. The market is also expected to gain from the prevailing trend of preventive healthcare and laboratory consolidation. These trends have stoked the demand for laboratory automation and integration, in turn creating a landscape filled with opportunities for the global automated immunoassay analyzers market. With the demand for result comparability and international standardization scaling high, the use of automated immunoassay analyzers is likely to increase in the forthcoming years.

On the back of rising adoption of advanced technologies, the global automated immunoassay analyzers market is expected to expand considerably in the coming years. While in developed nations, the market will remaining steady, growth is likely to pace up in emerging nations. Besides rising disposable income of consumers, favorable government initiatives and investment toward betterment of the healthcare infrastructure, will help the automated immunoassay market stay strong in emerging nations.

Declining Reimbursement Facilities May Limit Market’s Scope in Developed Nations

On the downside, reeling under cost constraints, smaller diagnostic laboratories will find it particularly difficult to adopt automated immunoassay analyzers. Meanwhile in developed markets, the laboratories may face challenges on account of the declining reimbursements. Such factors are capable of restraining the market’s growth to an extent. Besides these, stringent regulations and the need for operating under escalating pricing pressures may adversely impact the market’s trajectory and also hamper the business flow of laboratories. Therefore, a majority of laboratories are focusing on high volume testing in order to boost profitability per test. In order to provide accurate diagnosis and perform specialized test, many of these laboratories have adopted automated systems. Such factors are likely to give the global automated immunoassay analyzers market significant impetus in the coming years.

Shreyas is a Digital Marketer by professional and he has a great experience in blogging, content writing and SEO

Insulin Pumps Market Slated to Value at US$9,550.7 Mn by the end of 2025

A recent intelligence study by Transparency Market Research (TMR) has detected that the global insulin pumps market is consolidated among top three companies, who accounted for more than 50% of the shares in 2016, whereas the rest of the market is fragmented, distributed among a large number of domestic and regional players. This report projects the demand in the global insulin pumps market to increment at a robust CAGR of 9.8% during the forecast period of 2017 to 2025, reaching a valuation of US$9,550.7 mn in 2025, notably up from its evaluated worth of US$4,180.4 mn in 2016.

As far as the competitive landscape is concerned, the rivalry will intensify in the near future with the influx of several new vendors. In addition to that, the existing players are expected to add to their market shares via implementation of new models as well as mergers and acquisitions. Some of the key companies currently operating in the global insulin pumps market are Cellnovo Group SA, Medtronic, F. Hoffmann-La Roche Ltd., Valeritas, Inc., Animas Corporation (Johnson & Johnson), SOOIL Developments Co., Ltd, Tandem Diabetes Care, Inc., Ypsomed AG, Insulet Corporation, and Jiangsu Delfu Co., Ltd.

Insulin Pumps Profitable Segment among Type-1 Diabetic Patients

Based on product, the global insulin pumps market has been segmented into insulin pumps including tethered pumps and disposable or patch insulin pumps and insulin pump supplies and accessories, which is further sub-segmented into insulin reservoirs or cartridges and infusion set insertion devices. In 2016, insulin pumps segment, with its sub-segments, collectively accounted for 70.1%, which was a reflection of several factors, such as high awareness about tethered insulin pumps among type-1 diabetes patients, growing adoption of technologically advanced products such as patch pumps, and increase in the prevalence of diabetes among the geriatric population. The report also detects that the global insulin pumps market is witnessing a preference of insulin pumps as a result of better efficiency offered by them in terms of dosage. Among distribution channel categories of hospital pharmacy, retail pharmacy, online sales, and diabetes clinics or centers, hospital pharmacy serves the maximum demand.

North America Serves Maximum Demand

Out of the five regions, North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa, studied by this report for the potential of insulin pumps market, North America is most profitable, accounting for 64.1% of the demand in 2016. The developed country of the U.S. coupled with increasing demand for advanced technology such as insulin pumps integrated with continuous monitoring system have led to the growth of insulin pumps market in the U.S., single-handedly propelling the North America market to sustain an edge over rest of the regions. Growing percentage of geriatrics, high structured healthcare sector, and availability of a well-defined reimbursement policies from public and private health insurance firms are some of the other factors helping the North America insulin pumps market.

Escalating Geriatrics Population Driving Demand

The demand in the global insulin pumps market is gaining traction from a number of factors, such as increasing prevalence of diabetes, increased focus on adult population, increasing disposable income, and growing public awareness due to the penetration of social media. On the other hand, high cost, availability of alternatives, and inadequate reimbursement policies in several emerging economies are some of the key factors challenging the insulin pumps market from attaining its true potential. Nevertheless, the vendors operating in the global insulin pumps market are expected to gain new revenue avenues from advances in insulin pumps and growing adoption against conventional methods.

Shreyas is a Digital Marketer by professional and he has a great experience in blogging, content writing and SEO

Dental Implants Market Slated to Value at US$6.54 Bn by the end of 2025

The global dental implants market that has been analyzed in a recent research report by Transparency Market Research (TMR) demonstrates a largely consolidated vendor landscape. This is because of several large players that operate globally and a few small players that operate in regional markets.

Some of the prominent names operating in the global market for dental implants are Straumann Holding AG, Dentsply Sirona Inc., Henry Schein Inc., Zimmer Biomet Holdings Inc., 3M Health Care, Danaher Corporation, Ivoclar Vivadent AG, and AVINENT Implant System S.L.

The global dental implants market is projected to expand at a modest CAGR of 6.9% between 2017 and 2025. This will result in the market to become worth US$6.54 bn by 2025 increasing from its valuation of US$3.60 bn in 2016.

Favorable Physical Properties of Titanium Boost Demand

By product type, endosteal implants led the dental implants market in 2016 accounting for more than 80% revenue-wise. The segment is expected to grow at a significant pace in the coming years too. The segment of titanium based on material type led the market in 2016 in terms of revenue. Titanium has been witnessing high demand due to its physical properties that are suitable for dental implants.

The dental clinics end-use segment is expected to continue to dominate the global market for dental implants over the forecast period between 2017 and 2025 in terms of revenue. The clinics end-use segment held more than 60% of the market in 2016 revenue-wise.

Need to Fix Permanent Loss due to Accident, Dental Disorders Drives Market

The key factor stoking growth of the global dental implants market is an increasing number of individuals suffering from periodontal diseases across the world. For example, according to data released by the Centers for Disease Control and Prevention (CDC), 47.2% of the population above the above the age of 30 years in the U.S. is suffering from some type of periodontal disease.

Age is a significant factor that is related to the occurrence of periodontal disorders. Tooth enamel tends to wear away with age, making the teeth susceptible to damage, dental plaques, and decay,” says an analyst at TMR. As per statistics of the World Health Organization, the elderly population across the world which stood at 524 million in 2010 is expected to reach almost 2 billion by 2050, to which developed countries such as the U.S., the U.K., Italy, and Germany will contribute significantly.

Some other growth drivers of the dental implants market are increasing prevalence of dental ailments, rising incidence of dental problems due to changing eating habits, and increasing number of accidents. In present times, changing eating habits, which includes high consumption of refined foods, due to changing lifestyle has been a significant factor for increased incidence of tooth decay at an early age.

Road accidents that account for significant number of accidents every year globally can sometimes lead to partial impairment or complete loss of body part, which includes the oral cavity. This may require a medical implant to make up for the lost body part.

Serving a roadblock to the market is the high price of dental implants and strict guidelines and regulations for the manufacture of innovative products.

Shreyas is a Digital Marketer by professional and he has a great experience in blogging, content writing and SEO